FDA panel declines to approve Pfizer boosters for all Americans
The independent FDA advisory committee voted "no" on Friday on the question of whether the current data supports a booster shot of the Pfizer vaccine for anyone 16 and older.
This was largely due to members’ discomfort with the vast age range this question includes. As members of the FDA's Vaccines and Related Biological Products Advisory Committee outlined in Friday's meeting, there are still large gaps in safety and efficacy data for the younger age groups. But the members said they haven't ruled out third shots for older populations.
The panel will now vote on boosters for everyone over 65 and people who are at high risk of the virus.